PBC Committee Opens The Door to $2.2B Opportunity For Intercept Pharma (ICPT) - Wedbush

Needham & Company Reiterates Buy on Intercept Pharma (ICPT) Following Positive FDA Panel Vote on Obeticholic Acid

Needham & Company reiterated a Buy rating and $350.00 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) following an FDA panel vote in favor of Obeticholic Acid approval.

Analyst Alan Carr commented, "The FDA Gastrointestinal Drugs Advisory Committee voted yesterday 17-0 in favor of Obeticholic Acid... More

Intercept Pharmaceuticals (ICPT) Briefing Docs 'Mostly In-Line' - FBR Capital

FBR Capital analyst Vernon Bernardino reiterated a Market Perform rating and $192 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) the FDA released briefing documents ahead of the April 7 meeting of its Gastrointestinal Drugs Advisory Committee (GIDAC) to discuss ICPT's new New Drug Application (NDA) for approval to use obeticholic acid (OCA), which is the company's investigational treatment for primary... More

Baird Maintains Bullish View on Intercept Pharmaceuticals (ICPT) Following Positive Briefing Docs

Baird analyst Brian Skorney reiterated an Outperform rating and $332 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) following positive FDA briefing documents.

Skorney commented, "Though we admit being scared by FDA's three-month delay, today's briefing docs are, what's the word?... More

Intercept Pharma (ICPT) Briefing Docs Raise New Questions, But All Appear Addressable - Leerink

Leerink affirms Intercept Pharma (Nasdaq: ICPT) at Market Perform with a price target of $144 as OCA briefing docs were posted ahead of an FDA panel this week.

ANalyst Joseph Schwartz commented, the FDA briefing documents for obeticholic acid (OCA) were released this morning and are largely in line with our recently-outlined expectations (LINK) and we maintain our opinion that ICPT is likely to receive a positive panel vote on Thursday, 4/7, and secure approval in the primary biliary cholangitis (PBC) indication by... More

Wells Fargo Upgrades Intercept Pharmaceuticals (ICPT) to Outperform

Wells Fargo upgraded Intercept Pharmaceuticals (NASDAQ: ICPT) from Market Perform to Outperform.

For an analyst ratings summary and ratings history on Intercept Pharmaceuticals click here. For more ratings news on Intercept Pharmaceuticals click here.

Shares of Intercept Pharmaceuticals closed at $133.55 yesterday.

Intercept Pharma (ICPT) FDA Briefing Documents Posted

Intercept Pharma (NASDAQ: ICPT) FDA briefing documents posted. LINK